[Carcinogen activity of the new drug thymodepressin studied in chronic tests on rats and mice].
The new drug thymodepressin was subcutaneously injected in doses 0.0145 and 0.145 mg/kg in rats and mice over a period of 104 weeks. No statistically significant difference in the tumor frequencies between the test and control groups was observed during this period of time. It is concluded that thymodepressin is not carcinogenic.